Apr 24, 2019 - While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.
Apr 24, 2019 - Novartis (NVS) beats on Q1 earnings, sales marginally miss estimates.
Apr 23, 2019 - Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apr 12, 2019 - Top Analyst Reports for Bank of America, Amgen & NextEra Energy
Apr 12, 2019 - Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
Apr 10, 2019 - Key highlights of the past week are new drug approvals, collaborations and pipeline updates.
Apr 05, 2019 - Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Apr 04, 2019 - Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets approval in EU after being approved in the United States last September.
Apr 04, 2019 - Novartis' (NVS) generic arm Sandoz resubmits its BLA for the proposed biosimilar of Neulasta.
Mar 27, 2019 - Key highlights of the past week are multiple study failures and other pipeline updates.